mdlinx mdlinx

MDLinx E-mail Article

To email this article, enter your own "From Email" address, the recipient's "To Email" address, and click the "Send Email" button. You may send to up to 5 emails at a time.


* From Email: 
* To Email: 
To Email: 
To Email: 
To Email: 
To Email: 
Email Subject Line: 
Comments:

Pathologic Changes in Breast Cancer After Anti-Estrogen Therapy

Samarnthai N et al. – These findings indicate increased differentiation of the tumor cells in response to anti–estrogen therapy and that may correlate with clinical response.

Methods
  • Authors reviewed a cohort of patients who received preoperative anti–estrogen therapy after baseline biopsy and then had a repeat biopsy after several weeks on treatment.
  • Patients with estrogen receptor positive tumors received anastrozole and fulvestrant in combination with gefitinib.
  • Core needle biopsies were performed at day 1 and 21, and tumors were completely excised if operable at day 112.
  • All patients were postmenopausal.

Results
  • Following treatment, tumors had degenerative changes including smudged nuclei, decreased nuclear size, intranuclear vacuoles, vacuolated cytoplasm, and increased cellular discohesion.
  • In addition, increased tubule formation and intracytoplasmic lumina were seen in 6/9 cases (66.7%) and decreased mitotic rate was demonstrated in 7/9 cases (77.8%).
[more...]

Register now to view all the MDLinx contents (FREE)!

  • Stay current on the latest literature, research and clinical news
  • Get special communications and offers from MDLinx and our sponsors
  • Receive invitations to paid market research
View Samples and Register

Stay current - Media Tool

Newsletter
RSS
Follow Us
Facebook

Receive free subspecialty
"5-minute updates" via email

Sign up!

Send the E-mail Newsletter to a Colleague


Send

Subscribe to our free RSS feeds:
Get the latest news in your specialty automatically added to your newsreader or your personal My Yahoo!, Google, My MSN or My AOL page. Learn More

Follow Us on Twitter
Twitter is a rich source of instantly updated information. Join today and follow @MDLinx to start receiving tweets. Learn More

Close